Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | osteosarcoma | Research

Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis

Authors: Esha Baidya Kayal, Sameer Bakhshi, Devasenathipathy Kandasamy, Mehar Chand Sharma, Shah Alam Khan, Venkatesan Sampath Kumar, Kedar Khare, Raju Sharma, Amit Mehndiratta

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Early prediction of response to neoadjuvant chemotherapy (NACT) is important to aid personalized treatment in osteosarcoma. Diffusion-weighted Intravoxel Incoherent Motion (IVIM) MRI was used to evaluate the predictive value for response to NACT and survival outcome in osteosarcoma.

Methods

Total fifty-five patients with biopsy-proven osteosarcoma were recruited prospectively, among them 35 patients were further analysed. Patients underwent 3 cycles of NACT (Cisplatin + Doxorubicin) followed by surgery and response adapted adjuvant chemotherapy. Treatment outcomes were histopathological response to NACT (good-response ≥ 50% necrosis and poor-response < 50% necrosis) and survival outcome (event-free survival (EFS) and overall survival (OS)). IVIM MRI was acquired at 1.5T at baseline (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Quantitative IVIM parameters (D, D*, f & D*.f) were estimated using advanced state-of-the-art spatial penalty based IVIM analysis method bi-exponential model with total-variation penalty function (BETV) at 3 time-points and histogram analysis was performed.

Results

Good-responders: Poor-responders ratio was 13 (37%):22 (63%). EFS and OS were 31% and 69% with 16.27 and 25.9 months of median duration respectively. For predicting poor-response to NACT, IVIM parameters showed AUC = 0.87, Sensitivity = 86%, Specificity = 77% at t0, and AUC = 0.96, Sensitivity = 86%, Specificity = 100% at t1. Multivariate Cox regression analysis showed smaller tumour volume (HR = 1.002, p = 0.001) higher ADC-25th-percentile (HR = 0.047, p = 0.005) & D-Mean (HR = 0.1, p = 0.023) and lower D*-Mean (HR = 1.052, p = 0.039) were independent predictors of longer EFS (log-rank p-values: 0.054, 0.0034, 0.0017, 0.0019 respectively) and non-metastatic disease (HR = 4.33, p < 10–3), smaller tumour-volume (HR = 1.001, p = 0.042), lower D*-Mean (HR = 1.045, p = 0.056) and higher D*.f-skewness (HR = 0.544, p = 0.048) were independent predictors of longer OS (log-rank p-values: < 10–3, 0.07, < 10–3, 0.019 respectively).

Conclusion

IVIM parameters obtained with a 1.5T scanner along with novel BETV method and their histogram analysis indicating tumour heterogeneity were informative in characterizing NACT response and survival outcome in osteosarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8(10):705–18. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8(10):705–18.
2.
go back to reference Mittal A, Pushpam D, Ganguly S, Kumar VS, Khan S, Bakhshi S. Mittal, A., Pushpam, D., Ganguly, S. et al. Controversies and challenges in the management of osteosarcoma—an Indian perspective. Indian J Surg Oncol. 2022; Mittal A, Pushpam D, Ganguly S, Kumar VS, Khan S, Bakhshi S. Mittal, A., Pushpam, D., Ganguly, S. et al. Controversies and challenges in the management of osteosarcoma—an Indian perspective. Indian J Surg Oncol. 2022;
3.
go back to reference Ramaswamy A, Rekhi B, Bakhshi S, Hingmire S, Agarwal M, Hospital TM, et al. Indian data on bone and soft tissue sarcomas: a summary of published study results. South Asian J Cancer. 2020;5(3):138–45. Ramaswamy A, Rekhi B, Bakhshi S, Hingmire S, Agarwal M, Hospital TM, et al. Indian data on bone and soft tissue sarcomas: a summary of published study results. South Asian J Cancer. 2020;5(3):138–45.
4.
go back to reference Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4(3):212–36. Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4(3):212–36.
7.
go back to reference Qiu Z, Du X, Chen K, Dai Y, Wang S, Xiao J, et al. Gene signatures with predictive and prognostic survival values in human osteosarcoma. PeerJ. 2021;15(9): e10633.CrossRef Qiu Z, Du X, Chen K, Dai Y, Wang S, Xiao J, et al. Gene signatures with predictive and prognostic survival values in human osteosarcoma. PeerJ. 2021;15(9): e10633.CrossRef
8.
go back to reference Brisse H, Ollivier L, Edeline V, Pacquement H, Michon J, Glorion C, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004;34(8):595–605.CrossRef Brisse H, Ollivier L, Edeline V, Pacquement H, Michon J, Glorion C, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004;34(8):595–605.CrossRef
11.
go back to reference Kubo T, Furuta T, Johan MP, Ochi M, Adachi N. Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: a meta-analysis. Mol Clin Oncol. 2017;7(1):88–92.CrossRef Kubo T, Furuta T, Johan MP, Ochi M, Adachi N. Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: a meta-analysis. Mol Clin Oncol. 2017;7(1):88–92.CrossRef
12.
go back to reference Wang C, Du L, Si M, Yin Q, Chen L, Shu M, et al. Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. PLoS ONE. 2013;8(8): e72679.CrossRef Wang C, Du L, Si M, Yin Q, Chen L, Shu M, et al. Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. PLoS ONE. 2013;8(8): e72679.CrossRef
14.
go back to reference Bajpai J, Gamnagatti S, Kumar R, Sreenivas V, Sharma MC, Khan SA, et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol. 2011;41(4):441–50.CrossRef Bajpai J, Gamnagatti S, Kumar R, Sreenivas V, Sharma MC, Khan SA, et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol. 2011;41(4):441–50.CrossRef
15.
go back to reference Oka K, Yakushiji T, Sato H, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skelet Radiol. 2010;39:141–6.CrossRef Oka K, Yakushiji T, Sato H, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skelet Radiol. 2010;39:141–6.CrossRef
16.
go back to reference Shuliang Z, Yi S, Jinghao D, Qingtao Q, Xingping G, Aijie W, et al. Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma. J Bone Onchology. 2019;19(September): 100263. Shuliang Z, Yi S, Jinghao D, Qingtao Q, Xingping G, Aijie W, et al. Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma. J Bone Onchology. 2019;19(September): 100263.
17.
go back to reference Ki S, Id L, Id WJ, Jung CK, Im SA, Chung N, et al. Prediction of poor responders to neoadjuvant chemotherapy in patients with osteosarcoma: additive value of diffusion-weighted MRI including volumetric analysis to standard MRI at 3T. PLoS ONE. 2020;15(3): e0229983.CrossRef Ki S, Id L, Id WJ, Jung CK, Im SA, Chung N, et al. Prediction of poor responders to neoadjuvant chemotherapy in patients with osteosarcoma: additive value of diffusion-weighted MRI including volumetric analysis to standard MRI at 3T. PLoS ONE. 2020;15(3): e0229983.CrossRef
18.
go back to reference van der Woude H-J, Bioem JL, Verstraete KL, Taminiau AHM, Nooy MA, Hogendoorn PCW. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic imaging in detecting viable tumor before surgery. Am J Roentgenol. 1995;165(3):593–8.CrossRef van der Woude H-J, Bioem JL, Verstraete KL, Taminiau AHM, Nooy MA, Hogendoorn PCW. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic imaging in detecting viable tumor before surgery. Am J Roentgenol. 1995;165(3):593–8.CrossRef
19.
go back to reference Amit P, Malhotra A, Kumar R, Kumar L, Patro D, Elangovan S. Evaluation of static and dynamic MRI for assessing response of bone sarcomas to preoperative chemotherapy: correlation with histological necrosis. Indian J Radiol Imaging. 2015;25(3):269.CrossRef Amit P, Malhotra A, Kumar R, Kumar L, Patro D, Elangovan S. Evaluation of static and dynamic MRI for assessing response of bone sarcomas to preoperative chemotherapy: correlation with histological necrosis. Indian J Radiol Imaging. 2015;25(3):269.CrossRef
20.
go back to reference Song H, Jiao Y, Wei W, Ren X, Shen C, Qiu Z, et al. Can pretreatment 18 F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy? Eur Radiol. 2019;29:3945–54.CrossRef Song H, Jiao Y, Wei W, Ren X, Shen C, Qiu Z, et al. Can pretreatment 18 F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy? Eur Radiol. 2019;29:3945–54.CrossRef
22.
go back to reference Lin P, Yang P, Chen S, Shao Y, Xu L, Wu Y, et al. A Delta-radiomics model for preoperative evaluation of neoadjuvant chemotherapy response in high-grade osteosarcoma. Cancer Imaging. 2020;20(7):1–12. Lin P, Yang P, Chen S, Shao Y, Xu L, Wu Y, et al. A Delta-radiomics model for preoperative evaluation of neoadjuvant chemotherapy response in high-grade osteosarcoma. Cancer Imaging. 2020;20(7):1–12.
23.
go back to reference Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-bodere F, et al. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE. 2017;12(8): e0183841.CrossRef Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-bodere F, et al. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE. 2017;12(8): e0183841.CrossRef
24.
go back to reference Bajpai J, Kumar R, Sreenivas V, Sharma MC, Khan SA, Rastogi S, Malhotra A, Gamnagatti S, Kumar R, Safaya R, Bakhshi S. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis. J Pediatr Hematol Oncol. 2011;33(7):e271–8.CrossRef Bajpai J, Kumar R, Sreenivas V, Sharma MC, Khan SA, Rastogi S, Malhotra A, Gamnagatti S, Kumar R, Safaya R, Bakhshi S. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis. J Pediatr Hematol Oncol. 2011;33(7):e271–8.CrossRef
25.
go back to reference Bajpai J, Gamanagatti S, Sharma MC, Kumar R, Vishnubhatla S, Khan SA, Rastogi S, Malhotra A, Bakhshi S. Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer. 2010;54(4):526–31. Bajpai J, Gamanagatti S, Sharma MC, Kumar R, Vishnubhatla S, Khan SA, Rastogi S, Malhotra A, Bakhshi S. Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer. 2010;54(4):526–31.
26.
go back to reference Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, Rastogi S, Malhotra A, Bakhshi S. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53(6):1035–9.CrossRef Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, Rastogi S, Malhotra A, Bakhshi S. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53(6):1035–9.CrossRef
27.
go back to reference Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168(2):497–505.CrossRef Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168(2):497–505.CrossRef
29.
go back to reference Koh D, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol. 2011;196(6):1351–61.CrossRef Koh D, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol. 2011;196(6):1351–61.CrossRef
32.
go back to reference Li X, Wang P, Li D, Zhu H, Meng L, Song Y, et al. Intravoxel incoherent motion MR imaging of early cervical carcinoma: correlation between imaging parameters and tumor-stroma ratio. Eur Radiol. 2018;28(5):1875–83.CrossRef Li X, Wang P, Li D, Zhu H, Meng L, Song Y, et al. Intravoxel incoherent motion MR imaging of early cervical carcinoma: correlation between imaging parameters and tumor-stroma ratio. Eur Radiol. 2018;28(5):1875–83.CrossRef
33.
go back to reference Fujima N, Yoshida D, Sakashita T, Homma A, Tsukahara A, Shimizu Y, et al. Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients. Eur Radiol. 2017;27(3):956–65.CrossRef Fujima N, Yoshida D, Sakashita T, Homma A, Tsukahara A, Shimizu Y, et al. Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients. Eur Radiol. 2017;27(3):956–65.CrossRef
34.
go back to reference Xiao Y, Pan J, Chen Y, Chen Y, He Z, Zheng X. Intravoxel incoherent motion-magnetic resonance imaging as an early predictor of treatment response to neoadjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Med. 2015;94(24): e973.CrossRef Xiao Y, Pan J, Chen Y, Chen Y, He Z, Zheng X. Intravoxel incoherent motion-magnetic resonance imaging as an early predictor of treatment response to neoadjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Med. 2015;94(24): e973.CrossRef
35.
go back to reference Bedair R, Priest AN, Patterson AJ, McLean MA, Graves MJ, Manavaki R, et al. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations. Eur Radiol. 2017;27(7):2726–36.CrossRef Bedair R, Priest AN, Patterson AJ, McLean MA, Graves MJ, Manavaki R, et al. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations. Eur Radiol. 2017;27(7):2726–36.CrossRef
36.
go back to reference Chen B, Shao Y, Lin Z, Hsu C, Cheng A, Hsu C, et al. Dynamic contrast-enhanced and intravoxel incoherent motion MRI biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma. Diagnostics. 2021;11(1340):1–14. Chen B, Shao Y, Lin Z, Hsu C, Cheng A, Hsu C, et al. Dynamic contrast-enhanced and intravoxel incoherent motion MRI biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma. Diagnostics. 2021;11(1340):1–14.
38.
go back to reference Zuo H. The Value of Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in the Evaluation of the Osteosarcoma Response to Preoperative Neoadjuvant Chemotherapy in Teens. Concepts Magn Reson Part A. 2019;2019(Article ID 2918763):1–8. Zuo H. The Value of Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in the Evaluation of the Osteosarcoma Response to Preoperative Neoadjuvant Chemotherapy in Teens. Concepts Magn Reson Part A. 2019;2019(Article ID 2918763):1–8.
39.
go back to reference Baidya Kayal E, Kandasamy D, Khare K, Alampally JT, Bakhshi S, Sharma R, et al. Quantitative analysis of intravoxel incoherent motion (IVIM) diffusion MRI using total variation and huber penalty function. Med Phys. 2017;44(11):5489–858. Baidya Kayal E, Kandasamy D, Khare K, Alampally JT, Bakhshi S, Sharma R, et al. Quantitative analysis of intravoxel incoherent motion (IVIM) diffusion MRI using total variation and huber penalty function. Med Phys. 2017;44(11):5489–858.
40.
go back to reference Kayal EB, Devasenathipathy K, Khare K, Alampally JT, Bakhshi S, Sharma R, Mehndiratta A. Novel strategy for quantitative analysis of IVIM Diffusion MRI in Ewing’s Sarcoma Family of Tumours. In: Proc Intl Soc Mag Reson Med 24. 2016. p. 1–3. Kayal EB, Devasenathipathy K, Khare K, Alampally JT, Bakhshi S, Sharma R, Mehndiratta A. Novel strategy for quantitative analysis of IVIM Diffusion MRI in Ewing’s Sarcoma Family of Tumours. In: Proc Intl Soc Mag Reson Med 24. 2016. p. 1–3.
41.
go back to reference Malagi AV, Kandasamy D, Khare K, Pushpam D, Kumar R, Bakhshi S, Mehndiratta A. IVIM & diffusion kurtosis mr imaging on interim response assessment of hodgkin lymphoma. In: Proc Intl Soc Mag Reson Med 28. 2020. p. 1–3. Malagi AV, Kandasamy D, Khare K, Pushpam D, Kumar R, Bakhshi S, Mehndiratta A. IVIM & diffusion kurtosis mr imaging on interim response assessment of hodgkin lymphoma. In: Proc Intl Soc Mag Reson Med 28. 2020. p. 1–3.
42.
go back to reference Vij M, Malagi A V., Baidya Kayal E, Saini J, Mehndiratta A. IVIM analysis using Total Variation Penalty Regularization Based Model for Brain Tumor Analysis. In: Proc Intl Soc Mag Reson Med 28. 2020. p. 1–4. Vij M, Malagi A V., Baidya Kayal E, Saini J, Mehndiratta A. IVIM analysis using Total Variation Penalty Regularization Based Model for Brain Tumor Analysis. In: Proc Intl Soc Mag Reson Med 28. 2020. p. 1–4.
45.
go back to reference The ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Supplement 7):100–9. The ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Supplement 7):100–9.
46.
go back to reference Nataraj V, Rastogi S, Khan SA, Sharma M, Agarwala S, Vishnubhatla S, Bakhshi S. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients. Clin Transl Oncol. 2016;18(9):937–44.CrossRef Nataraj V, Rastogi S, Khan SA, Sharma M, Agarwala S, Vishnubhatla S, Bakhshi S. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients. Clin Transl Oncol. 2016;18(9):937–44.CrossRef
47.
go back to reference Nataraj V, Batra A, Rastogi S, Khan S, Sharma M, Vishnubhatla S, Bakhshi S. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: a single- center experience of 237 patients. J Surg Oncol. 2015;112(6):662–8.CrossRef Nataraj V, Batra A, Rastogi S, Khan S, Sharma M, Vishnubhatla S, Bakhshi S. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: a single- center experience of 237 patients. J Surg Oncol. 2015;112(6):662–8.CrossRef
48.
go back to reference Bihan LE. The Capillary network: a link between IVIM and classical perfusion. Magn Reson Med. 1992;27(1):171–8.CrossRef Bihan LE. The Capillary network: a link between IVIM and classical perfusion. Magn Reson Med. 1992;27(1):171–8.CrossRef
49.
go back to reference Pencina MJ, Agostino RBD. Overall C as a measure of discrimination in survival analysis: model speciÿc population value and conÿdence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRef Pencina MJ, Agostino RBD. Overall C as a measure of discrimination in survival analysis: model speciÿc population value and conÿdence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRef
50.
go back to reference Newson R. Confidence intervals for rank statistics: Somers ’ D and extensions. Stata J. 2006;6(3):309–34.CrossRef Newson R. Confidence intervals for rank statistics: Somers ’ D and extensions. Stata J. 2006;6(3):309–34.CrossRef
51.
go back to reference Christensen E. Snecial articles multivariate survival analysis using Cox’s regression model. Hepatology. 1987;7(6):1346–58.CrossRef Christensen E. Snecial articles multivariate survival analysis using Cox’s regression model. Hepatology. 1987;7(6):1346–58.CrossRef
52.
go back to reference Tatum JL, Kelloff GJ, Gillies RJ. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82(10):699–757.CrossRef Tatum JL, Kelloff GJ, Gillies RJ. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82(10):699–757.CrossRef
53.
go back to reference Lee H, Rha SY, Chung YE, Shim HS, Kim YJ, Hur J, et al. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Magn Reson Med. 2014;71(4):1554–8.CrossRef Lee H, Rha SY, Chung YE, Shim HS, Kim YJ, Hur J, et al. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Magn Reson Med. 2014;71(4):1554–8.CrossRef
54.
go back to reference Andreou A, Koh DM, Collins DJ, Blackledge M, Wallace T, Leach MO, et al. Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol. 2013;23(2):428–34.CrossRef Andreou A, Koh DM, Collins DJ, Blackledge M, Wallace T, Leach MO, et al. Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol. 2013;23(2):428–34.CrossRef
55.
go back to reference Rudin LI, Osher S, Fatemi E. Nonlinear total variation based noise removal algorithms. Phys D. 1992;60(1–4):259–68.CrossRef Rudin LI, Osher S, Fatemi E. Nonlinear total variation based noise removal algorithms. Phys D. 1992;60(1–4):259–68.CrossRef
56.
go back to reference Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer. 1985;56(7):1515–21.CrossRef Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer. 1985;56(7):1515–21.CrossRef
Metadata
Title
Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
Authors
Esha Baidya Kayal
Sameer Bakhshi
Devasenathipathy Kandasamy
Mehar Chand Sharma
Shah Alam Khan
Venkatesan Sampath Kumar
Kedar Khare
Raju Sharma
Amit Mehndiratta
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03838-1

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.